Literature DB >> 25045621

After 40 years, new medicine for combating TB.

Mehdi Mirsaeidi1.   

Abstract

Entities:  

Year:  2013        PMID： 25045621      PMCID： PMC4103685          DOI： 10.1016/j.ijmyco.2013.01.004

Source DB:  PubMed          Journal:  Int J Mycobacteriol        ISSN： 2212-5531


× No keyword cloud information.
  10 in total

1.  Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis.

Authors:  Rokeya Tasneen; Si-Yang Li; Charles A Peloquin; Dinesh Taylor; Kathy N Williams; Koen Andries; Khisimuzi E Mdluli; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

2.  Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells.

Authors:  Jasvir Dhillon; Koen Andries; Patrick P J Phillips; Denis A Mitchison
Journal:  Tuberculosis (Edinb)       Date:  2010-08-21       Impact factor: 3.131

3.  A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.

Authors:  Koen Andries; Peter Verhasselt; Jerome Guillemont; Hinrich W H Göhlmann; Jean-Marc Neefs; Hans Winkler; Jef Van Gestel; Philip Timmerman; Min Zhu; Ennis Lee; Peter Williams; Didier de Chaffoy; Emma Huitric; Sven Hoffner; Emmanuelle Cambau; Chantal Truffot-Pernot; Nacer Lounis; Vincent Jarlier
Journal:  Science       Date:  2004-12-09       Impact factor: 47.728

Review 4.  Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control.

Authors:  Alberto Matteelli; Giovanni Battista Migliori; Daniela Cirillo; Rosella Centis; Enrico Girard; Mario Raviglion
Journal:  Expert Rev Anti Infect Ther       Date:  2007-10       Impact factor: 5.091

5.  The diarylquinoline TMC207 for multidrug-resistant tuberculosis.

Authors:  Andreas H Diacon; Alexander Pym; Martin Grobusch; Ramonde Patientia; Roxana Rustomjee; Liesl Page-Shipp; Christoffel Pistorius; Rene Krause; Mampedi Bogoshi; Gavin Churchyard; Amour Venter; Jenny Allen; Juan Carlos Palomino; Tine De Marez; Rolf P G van Heeswijk; Nacer Lounis; Paul Meyvisch; Johan Verbeeck; Wim Parys; Karel de Beule; Koen Andries; David F Mc Neeley
Journal:  N Engl J Med       Date:  2009-06-04       Impact factor: 91.245

6.  Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.

Authors:  A H Diacon; P R Donald; A Pym; M Grobusch; R F Patientia; R Mahanyele; N Bantubani; R Narasimooloo; T De Marez; R van Heeswijk; N Lounis; P Meyvisch; K Andries; D F McNeeley
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

7.  Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection.

Authors:  Tianyu Zhang; Si-Yang Li; Kathy N Williams; Koen Andries; Eric L Nuermberger
Journal:  Am J Respir Crit Care Med       Date:  2011-06-09       Impact factor: 21.405

8.  Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267.

Authors:  Kelly E Dooley; Jeong-Gun Park; Susan Swindells; Reena Allen; David W Haas; Yoninah Cramer; Francesca Aweeka; Ilene Wiggins; Amita Gupta; Patricia Lizak; Sonia Qasba; Rolf van Heeswijk; Charles Flexner
Journal:  J Acquir Immune Defic Syndr       Date:  2012-04-15       Impact factor: 3.731

9.  New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure.

Authors:  Elena Segala; Wladimir Sougakoff; Aurelie Nevejans-Chauffour; Vincent Jarlier; Stephanie Petrella
Journal:  Antimicrob Agents Chemother       Date:  2012-02-21       Impact factor: 5.191

10.  Variations of subunit {varepsilon} of the Mycobacterium tuberculosis F1Fo ATP synthase and a novel model for mechanism of action of the tuberculosis drug TMC207.

Authors:  Goran Biukovic; Sandip Basak; Malathy Sony Subramanian Manimekalai; Sankaranarayanan Rishikesan; Manfred Roessle; Thomas Dick; Srinivasa P S Rao; Cornelia Hunke; Gerhard Grüber
Journal:  Antimicrob Agents Chemother       Date:  2012-10-22       Impact factor: 5.191
  10 in total
  2 in total

1.  Bio-layer interferometry for measuring kinetics of protein-protein interactions and allosteric ligand effects.

Authors:  Naman B Shah; Thomas M Duncan
Journal:  J Vis Exp       Date:  2014-02-18       Impact factor: 1.355

2.  Multidrug-resistant tuberculosis treatment with linezolid-containing regimen.

Authors:  Maham Farshidpour; Golnaz Ebrahimi; Mehdi Mirsaeidi
Journal:  Int J Mycobacteriol       Date:  2013-12-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.